C3 Jian gets a $60M round from some unconventional investors

LA-based C3 Jian has rounded up some players in the dental industry to provide a $60.5 million D round designed to get its lead therapy to prevent tooth decay through a mid-stage study while advancing a follow-up program produced with the biotech's platform technology.

C3-Jian is advancing C16G2, a peptide-based antimicrobial drug which targets Streptococcus mutans, a bacterium that causes tooth decay. And the national dental insurance holding company Renaissance along with dental benefits administrators tied to Delta Dental were credited with earlier investors for the new round. The Phase II is designed to study C16G2 formulated as a mouth rinse and a gel.

The biotech says there's another therapy coming along that promises to spur the remineralization of teeth.

"The support of our shareholders has allowed us to advance our lead product to Phase 2 FDA testing, as well as expand our pipeline portfolio," Todd Patrick, C3 Jian's president and CEO, said in a statement.m"With new Delta Dental companies joining in, we are well positioned to take C16G2 through Phase II in both adults and children, and also explore the potential of the STAMP platform in other applications, although we will maintain our focus on oral healthcare."

- here's the release

Suggested Articles

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.

Grid Therapeutics is planning to start trials of its lead cancer immunotherapy GT103 next year after raising $5 million in second-round financing.

The IPO comes as the Flagship startup prepares to test its lead inflammatory disease and anticancer microbial strains in humans.